Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Pancreatic Cancer | Research

Use of period analysis to provide a timely assessment of 5-year relative survival for pancreatic cancer patients from Taizhou, eastern China

Authors: Ye Lu, Min He, Liyou Lian, Huijun Lei, Yongran Cheng, Liangyou Wang, Tianhui Chen, Jinfei Chen

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Assessing long-term tumor survival rates is crucial for evaluating the effectiveness of tumor treatment and burden. However, timely assessment of long-term survival in patients with pancreatic cancer is lagging in China. In this study, we applied period analysis to estimate the long-term survival of pancreatic cancer patients using data from four population-based cancer registries in Taizhou city, eastern China. A total of 1121 patients diagnosed with pancreatic cancer between 2004 and 2018 were included. We assessed the 5-year relative survival (RS) using period analysis and further stratified by sex, age at diagnosis, and region. The 5-year RS during 2014–2018 overall reached 18.9% (14.7% for men and 23.3% for women, respectively). A decrease of the 5-year RS from 30.3% to 11.2% was observed in four diagnostic age gradients (< 55, 55–64, 65–74, and > 74 years age groups). The 5-year RS was higher in urban (24.2%) than in rural (17.4%) areas. Moreover, the 5-year RS of pancreatic cancer patients showed an overall increasing trend for the three periods (2004–2008, 2009–2013, and 2014–2018). Our study, using period analysis for the first time in China, provides the latest estimates of the survival of patients with pancreatic cancer, which provides essential evidence for the prevention and intervention of pancreatic cancer. The results also indicate the importance of further applications of the period analysis for more up-to-date and accurate survival estimates.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
go back to reference Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide Burden of, risk factors for, and Trends in Pancreatic Cancer. Gastroenterology. 2021;160:744–54.CrossRefPubMed Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide Burden of, risk factors for, and Trends in Pancreatic Cancer. Gastroenterology. 2021;160:744–54.CrossRefPubMed
3.
go back to reference Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.CrossRefPubMed Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.CrossRefPubMed
4.
go back to reference Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4:934–47.CrossRef Pourshams A, Sepanlou SG, Ikuta KS, Bisignano C, Safiri S, Roshandel G, et al. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4:934–47.CrossRef
5.
go back to reference Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun. 2019;39:202–13. Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun. 2019;39:202–13.
6.
go back to reference Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1–9.CrossRef Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2:1–9.CrossRef
7.
go back to reference Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with Cancer by Period Analysis. J Clin Oncol. 2002;20:826–32.CrossRefPubMed Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with Cancer by Period Analysis. J Clin Oncol. 2002;20:826–32.CrossRefPubMed
8.
go back to reference Brenner H, Hakulinen T. Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision. J Clin Epidemiol. 2006;59:570–5.CrossRefPubMed Brenner H, Hakulinen T. Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision. J Clin Epidemiol. 2006;59:570–5.CrossRefPubMed
9.
go back to reference Brenner H, Hakulinen T. Maximizing the benefits of model-based period analysis of cancer patient survival. Cancer Epidemiol Biomarkers Prev. 2007;16:1675–81.CrossRefPubMed Brenner H, Hakulinen T. Maximizing the benefits of model-based period analysis of cancer patient survival. Cancer Epidemiol Biomarkers Prev. 2007;16:1675–81.CrossRefPubMed
10.
go back to reference Booth S, Riley RD, Ensor J, Lambert PC, Rutherford MJ. Temporal recalibration for improving prognostic model development and risk predictions in settings where survival is improving over time. Int J Epidemiol. 2020;49:1316–25.CrossRefPubMedPubMedCentral Booth S, Riley RD, Ensor J, Lambert PC, Rutherford MJ. Temporal recalibration for improving prognostic model development and risk predictions in settings where survival is improving over time. Int J Epidemiol. 2020;49:1316–25.CrossRefPubMedPubMedCentral
11.
go back to reference Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006;164:689–96.CrossRefPubMed Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006;164:689–96.CrossRefPubMed
12.
go back to reference Jansen L, Castro FA, Gondos A, Krilaviciute A, Barnes B, Eberle A, et al. Recent cancer survival in Germany: an analysis of common and less common cancers. Int J Cancer. 2015;136:2649–58.CrossRefPubMed Jansen L, Castro FA, Gondos A, Krilaviciute A, Barnes B, Eberle A, et al. Recent cancer survival in Germany: an analysis of common and less common cancers. Int J Cancer. 2015;136:2649–58.CrossRefPubMed
13.
go back to reference Jansen L, Eberle A, Emrich K, Gondos A, Holleczek B, Kajüter H, et al. Socioeconomic deprivation and cancer survival in Germany: an ecological analysis in 200 districts in Germany. Int J Cancer. 2014;134:2951–60.CrossRefPubMed Jansen L, Eberle A, Emrich K, Gondos A, Holleczek B, Kajüter H, et al. Socioeconomic deprivation and cancer survival in Germany: an ecological analysis in 200 districts in Germany. Int J Cancer. 2014;134:2951–60.CrossRefPubMed
14.
go back to reference Holleczek B, Brenner H. Provision of breast cancer care and survival in Germany - results from a population-based high resolution study from Saarland. BMC Cancer. 2014;14:757. Holleczek B, Brenner H. Provision of breast cancer care and survival in Germany - results from a population-based high resolution study from Saarland. BMC Cancer. 2014;14:757.
15.
go back to reference Jiang X, Wang L, Cheng Y, Tang H, Chen T. Assessment of long-term survival of cancer patients using cancer registry data from eastern China: period analysis is superior to traditional methods. Int J Cancer. 2020;147:996–1005.CrossRefPubMed Jiang X, Wang L, Cheng Y, Tang H, Chen T. Assessment of long-term survival of cancer patients using cancer registry data from eastern China: period analysis is superior to traditional methods. Int J Cancer. 2020;147:996–1005.CrossRefPubMed
16.
go back to reference Li R, Zhang M, Cheng Y, Jiang X, Tang H, Wang L, et al. Using Population-Based Cancer Registration Data and Period Analysis to accurately assess and predict 5-Year relative survival for Lung Cancer Patients in Eastern China. Front Oncol. 2021;11:661012. Li R, Zhang M, Cheng Y, Jiang X, Tang H, Wang L, et al. Using Population-Based Cancer Registration Data and Period Analysis to accurately assess and predict 5-Year relative survival for Lung Cancer Patients in Eastern China. Front Oncol. 2021;11:661012.
18.
go back to reference Lu H, Li L, Cheng Y, Yang Z, Cao X, Zhang H, et al. Timely estimates of 5-Year relative survival for patients with cervical Cancer: a period analysis using Cancer Registry Data from Taizhou, Eastern China. Front Public Heal. 2022;10:926058. Lu H, Li L, Cheng Y, Yang Z, Cao X, Zhang H, et al. Timely estimates of 5-Year relative survival for patients with cervical Cancer: a period analysis using Cancer Registry Data from Taizhou, Eastern China. Front Public Heal. 2022;10:926058.
19.
go back to reference Wang Y, Zhang L, Han F, Li R, Cheng Y, Jiang X, et al. Using period analysis to Timely assess and predict 5-Year relative survival for Liver Cancer Patients from Taizhou, Eastern China. Front Oncol. 2022;12:920094. Wang Y, Zhang L, Han F, Li R, Cheng Y, Jiang X, et al. Using period analysis to Timely assess and predict 5-Year relative survival for Liver Cancer Patients from Taizhou, Eastern China. Front Oncol. 2022;12:920094.
20.
go back to reference Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Heal. 2018;6:e555–67.CrossRef Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Heal. 2018;6:e555–67.CrossRef
21.
go back to reference Holleczek B, Gondos A, Brenner H. Period R - an R package to calculate long-term cancer survival estimates using period analysis. Methods Inf Med. 2009;48:123–8.CrossRefPubMed Holleczek B, Gondos A, Brenner H. Period R - an R package to calculate long-term cancer survival estimates using period analysis. Methods Inf Med. 2009;48:123–8.CrossRefPubMed
22.
go back to reference Abdel-Rahman O. Impact of socioeconomic status on presentation, treatment and outcomes of patients with pancreatic cancer. J Comp Eff Res. 2020;9:1233–41.CrossRefPubMed Abdel-Rahman O. Impact of socioeconomic status on presentation, treatment and outcomes of patients with pancreatic cancer. J Comp Eff Res. 2020;9:1233–41.CrossRefPubMed
23.
go back to reference Bakens MJAM, Lemmens VEPP, de Hingh IHJT. Socio-economic status influences the likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands. Hpb. 2017;19:443–8.CrossRefPubMed Bakens MJAM, Lemmens VEPP, de Hingh IHJT. Socio-economic status influences the likelihood of undergoing surgical treatment for pancreatic cancer in the Netherlands. Hpb. 2017;19:443–8.CrossRefPubMed
24.
go back to reference Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust T, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20:1493–505.CrossRefPubMedPubMedCentral Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust T, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20:1493–505.CrossRefPubMedPubMedCentral
25.
go back to reference van Dongen JC, van der Geest LGM, de Meijer VE, van Santvoort HC, de Vos-Geelen J, Besselink MG, et al. Age and prognosis in patients with pancreatic cancer: a population-based study. Acta Oncol (Madr). 2022;61:286–93.CrossRef van Dongen JC, van der Geest LGM, de Meijer VE, van Santvoort HC, de Vos-Geelen J, Besselink MG, et al. Age and prognosis in patients with pancreatic cancer: a population-based study. Acta Oncol (Madr). 2022;61:286–93.CrossRef
26.
go back to reference McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846–61.CrossRefPubMedPubMedCentral McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846–61.CrossRefPubMedPubMedCentral
27.
go back to reference Principe DR, Rana A. Updated risk factors to inform early pancreatic cancer screening and identify high risk patients:pancreatic Cancer risk factors. Cancer Lett. 2020;485:56–65.CrossRefPubMedPubMedCentral Principe DR, Rana A. Updated risk factors to inform early pancreatic cancer screening and identify high risk patients:pancreatic Cancer risk factors. Cancer Lett. 2020;485:56–65.CrossRefPubMedPubMedCentral
28.
go back to reference Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, Schrag D, et al. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018;7:525–35.CrossRefPubMedPubMedCentral Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, Schrag D, et al. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018;7:525–35.CrossRefPubMedPubMedCentral
29.
go back to reference Li CH, Haider S, Shiah YJ, Thai K, Boutros PC. Sex differences in cancer driver genes and biomarkers. Cancer Res. 2018;78:5527–37.CrossRefPubMed Li CH, Haider S, Shiah YJ, Thai K, Boutros PC. Sex differences in cancer driver genes and biomarkers. Cancer Res. 2018;78:5527–37.CrossRefPubMed
30.
go back to reference Wang H, Liu J, Xia G, Lei S, Huang X, Huang X. Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study. Sci Rep. 2020;10:1–9. Wang H, Liu J, Xia G, Lei S, Huang X, Huang X. Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study. Sci Rep. 2020;10:1–9.
31.
go back to reference Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Uesaka K. Impact of patient age on the postoperative survival in pancreatic Head Cancer. Ann Surg Oncol. 2017;24:3220–8.CrossRefPubMed Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R, Uesaka K. Impact of patient age on the postoperative survival in pancreatic Head Cancer. Ann Surg Oncol. 2017;24:3220–8.CrossRefPubMed
32.
go back to reference Singh GK, Jemal A. Socioeconomic and Racial/Ethnic Disparities in Cancer Mortality, Incidence, and Survival in the United States, 1950–2014: Over Six Decades of Changing Patterns and Widening Inequalities. J Environ Public Health. 2017;2017:2819372. Singh GK, Jemal A. Socioeconomic and Racial/Ethnic Disparities in Cancer Mortality, Incidence, and Survival in the United States, 1950–2014: Over Six Decades of Changing Patterns and Widening Inequalities. J Environ Public Health. 2017;2017:2819372.
33.
go back to reference Wang YQ, Li HZ, Gong WW, Chen YY, Zhu C, Wang L, et al. Cancer incidence and mortality in Zhejiang Province, Southeast China, 2016: a population-based study. Chin Med J (Engl). 2021;134:1959–66.CrossRefPubMed Wang YQ, Li HZ, Gong WW, Chen YY, Zhu C, Wang L, et al. Cancer incidence and mortality in Zhejiang Province, Southeast China, 2016: a population-based study. Chin Med J (Engl). 2021;134:1959–66.CrossRefPubMed
34.
go back to reference Wang C, Rao K, Wu S, Liu Q. Health care in china improvement, challenges, and reform. Chest. 2013;143:524–31.CrossRefPubMed Wang C, Rao K, Wu S, Liu Q. Health care in china improvement, challenges, and reform. Chest. 2013;143:524–31.CrossRefPubMed
35.
go back to reference Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13:130. Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020;13:130.
36.
go back to reference Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 2020;21:e135–45.CrossRefPubMedPubMedCentral Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 2020;21:e135–45.CrossRefPubMedPubMedCentral
37.
go back to reference Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487–505.CrossRefPubMedPubMedCentral Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487–505.CrossRefPubMedPubMedCentral
Metadata
Title
Use of period analysis to provide a timely assessment of 5-year relative survival for pancreatic cancer patients from Taizhou, eastern China
Authors
Ye Lu
Min He
Liyou Lian
Huijun Lei
Yongran Cheng
Liangyou Wang
Tianhui Chen
Jinfei Chen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11119-3

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine